Global Metastatic Coloreal Cancer Market to Witness Robust Growth by 2035 – BIS Research

What is metastatic colorectal cancer? 

Metastatic colorectal cancer (mCRC) occurs when cancer originating in the colon or rectum spreads to distant organs (e.g., liver, lungs). It represents stage IV disease, often requiring systemic therapies like chemotherapy, targeted agents (e.g., EGFR or VEGF inhibitors), and immunotherapies. This advanced-stage cancer is typically incurable, focusing on prolonged survival and quality of life improvements. 

Request a sample report on Metastatic colorectal cancer market 

What is the Market Outlook? 

Hospitals, oncology centers, and specialized clinics are increasingly adopting targeted and immuno-oncology treatments, driving market momentum. Key trends include: 

• Rising uptake of EGFR inhibitors (cetuximab, panitumumab), VEGF inhibitors (bevacizumab), and newer targeted agents. 
• Integration of liquid biopsy (ctDNA) for MRD detection and therapy monitoring. 
• Personalized medicine, backed by biomarker testing and companion diagnostic tools. 
• Expanded diagnostic infrastructure in emerging markets, supported by public and private health initiatives. 

How Fast Is the Market Growing? 

The market is forecast to expand at a significant growth rate from 2025 to 2035, propelled by drug launches, enhanced screening programs, and the growing emphasis on personalized therapies and diagnostics. 

How Will This Report Help You? 

Planning to Enter the Market? 

• Access regional demand forecasts (North America, Europe, Asia-Pacific, Latin America). 
• Identify high-potential therapeutic segments: targeted therapies, immunotherapies, MRD diagnostics. 

Analyzing the Competitive Landscape? 

• Benchmark leading pharma and biotech firms. 
• Track drug development status, approvals, companion diagnostic rollouts, M&A, and licensing deals. 

Seeking R&D Insights? 

• Explore late-stage pipeline candidates: novel small molecules, bispecific antibodies, ctDNA diagnostic platforms. 
• Investigate emerging indications like MRD-guided adjuvant therapy. 

Interested in Regional Market Trends? 

• Compare technology adoption in developed versus emerging economies. 
• Understand diagnostic and reimbursement landscapes in various regions. 

Download complete TOC and Report Sample 

What Technologies Are Transforming the Market? 

• MRD detection via ctDNA liquid biopsy 
• Companion diagnostics for biomarker-driven therapies 
• Novel targeted agents (KRAS inhibitors, HER2), immunotherapy combinations 
• AI-enhanced diagnostics and digital pathology 
• Advanced genomic profiling tools 

Unlock Critical Insights with Surgical Procedure Database  

Discover BIS Research Surgical Procedure Volume Database – your key to real-world, country-level procedural insights across MedTech.   

What’s Driving Demand, Opportunity and Barriers? 

Drivers: 

• Rising global colorectal cancer burden 
• Shift toward precision medicine and biomarker-based treatment 
• Government initiatives for screening and diagnostics 

Restraints: 

• High prices of targeted and immunotherapies 
• Regulatory and reimbursement challenges for novel diagnostics in emerging markets 
• Complexity and cost of genomic testing 

Opportunities: 

• MRD-driven treatment tailoring and surveillance 
• Expansion in emerging markets with unmet diagnostic and therapeutic needs 
• Pharma–diagnostic partnerships for companion diagnostics 

Download the Complete TOC now! 

How Is the Market Segmented? 

by Drug Class 

•    Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors 

•    Anti-VEGF (Vascular Endothelial Growth Factor) Therapies 

•    Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies 

•    Immune Checkpoint Inhibitors 

•    Others 

by Region 

•    North America 

•    Europe  

•    Asia-Pacific 

Strategic Moves Shaping the Future: 

• Pharma–diagnostic collaborations for MRD companion tests 
• Regulatory fast-tracking and conditional approvals 
• Reimbursement policies favoring precision oncology 
• Infrastructure investments in core genomic labs and ctDNA platforms 

Case Study 

Pfizer’s KRAS G12C inhibitor + ctDNA companion test 

Pfizer launched its KRAS G12C small-molecule inhibitor alongside a liquid biopsy-based companion diagnostic in North America. Early adoption in academic centers showed a 20% improvement in median progression-free survival versus standard care, highlighting the clinical and commercial value of aligned diagnostic–therapeutic strategies. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Europe Hematologic Malignancies Testing Market 

Asia-Pacific Whole Genome and Exome Sequencing Market 

Europe Precision Medicine Software Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc